Archive for October 2017
FDA to Consider New Requirements for Opioid Packaging to Limit Exposure
The FDA is looking for creative approaches to the opioid crisis, including new requirements for product packaging, as ways to reduce overall exposure to the painkillers. Source: Drug Industry Daily
Read MoreAstraZeneca Continues to Divest Assets, Takes Stake in Mereo BioPharma With New Deal
Astra signed a licensing deal with Mereo BioPharma to out license the oral inhibitor of neutrophil elastase to the smaller Mereo. Source: BioSpace
Read MoreFosun Pharma to Buy France's Tridem for $73M
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa. Source: BioSpace
Read MoreThe Complicated Relationship Between Celgene and President Trump
On multiple occasions, President Donald Trump has aimed his ire at pharma companies. Source: BioSpace
Read MoreWhy Amazon Could be More Interested in Medical Devices Than Drugs
Amazon, as most everyone knows, has its fingers in a lot of pies. Source: BioSpace
Read MoreInsys Sales Execs Allegedly Made a Rap Video of Themselves Dancing With Their Deadly Fentanyl Spray
Insys continues to receive an optics beating in the wake of the charges against company founder John Kapoor and multiple executives surrounding illegal sales practices of its cancer pain drug. Source: BioSpace
Read MoreThis is the Fastest-Growing Private Pharma in the Bay Area
Want to work for a company having a growth spurt? Source: BioSpace
Read MoreShire in Talks to Sell 100-Employee Facility in Massachusetts
As part of consolidation program, Shire is looking to sell a manufacturing facility in Milford, MA that it gained through its 2015 acquisition of Baxalta. Source: BioSpace
Read MoreKymera Emerges Out of Stealth Mode With $30M and a Top Team of Drug Hunters
Kymera Therapeutics launched with a $30M Series A financing which was lead by Atlas Venture. Source: BioSpace
Read MoreMerck Drops After Withdrawing European App for Wonder Drug Keytruda
Late on Friday, Merck announced that it had pulled its application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous NSCLC from the EMA. Source: BioSpace
Read More